News & Press
2,000,000 TWO2 Treatments Milestone Reached as TWO2 Study Is Highlighted in Systemic Review of Topical Oxygen Therapies
The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds.
Dr. Mike Griffiths, President and CEO of Advanced Oxygen Therapy, Inc makes the cover of Healthcare Insights.
The cover story, “Advanced Oxygen Therapy, Inc: Dedicated To Resolving Acute And Chronic Wounds Through Its Unique Multi-Modality Two2 therapy,” details the company’s mission as it fights to help patients with chronic wounds.
Advanced Oxygen Therapy Inc. Named Among the 10 Most Innovative MedTech Solution Providers to Watch in 2021
AOTI announced today that it had been named among the 10 Most Innovative MedTech Solution Providers to Watch in 2021 by the journal The Healthcare Insights and is highlighted as the cover story of its May 2021 print edition.
Expansion of Topical Wound Oxygen (TWO2) Product Family Extends Treatment to Chronic Wound Patients with Larger Limbs, Venous and Diabetic Foot Ulcers
The addition of a new larger extremity-chamber to the company’s peripheral vascular disease (PVD) focused product line, allows for the application of TWO2 treatments for many more patients suffering from costly nonhealing chronic wounds.
Maintain Continuity-of-Care During the COVID-19 Pandemic
HELPING MAINTAIN CONTINUITY-OF-CARE DURING THE COVID-19 PANDEMIC TWO2 MULTI-MODALITY TOPICAL WOUND OXYGEN THERAPY PROVIDES PROVEN HEALING & WOUND PROTECTIVE CARE SAFELY FOR YOUR PATIENTS AT HOME (1) (2) (3)(1) Diabetes Care 2020; 43:616-624 (2) Vascular and...
Topical Wound Oxygen (TWO2) therapy Treats High-Risk Patients Safely at Home during the COVID-19 Pandemic
AOTI Inc. announced today that since the outbreak of the COVID-19 pandemic it has been focusing all its resources on supporting a growing number of wound care patients being treated at home by its unique multi-modality Topical Wound Oxygen (TWO2) therapy.
AOTI Inc.’s state of the art RCT receives editorial commentary in Diabetes Care, March 2020.
Breakthrough RCT Published in Leading ADA Journal “Diabetes Care” Shows Multi-Modality Topical Wound Oxygen (TWO2) Therapy is Six-Times More Effective Healing & Reducing Recurrence of Diabetic Foot Ulcers
AOTI Inc. today announced that a state-of-the-art Randomized Controlled Trial (RCT) demonstrating the efficacy of its unique multi-modality cyclical pressure Topical Wound Oxygen (TWO2) therapy in healing and reducing recurrence of Diabetic Foot Ulcers (DFU) has been...
AOTI Inc. Awarded New Five-Year Federal Supply Schedule Contract by the Department of Veterans Affairs
OCEANSIDE, Calif., June 19, 2019 /PRNewswire/ -- AOTI Inc. today announced that it has been awarded a new five-year Federal Supply Schedule (FSS) contract for its patented Topical Wound Oxygen (TWO2) therapy by the National Acquisition Center, U.S....
AOTI’s Topical Wound Oxygen (TWO2) Therapy Highlighted at Leading Worldwide Wound Care Conferences
It is clear there is a growing tsunami of interest in our products and their unprecedented complete healing benefits. We expect and hope that as our latest state-of-the-art Randomized Controlled Trial (RCT) is published that TWO2therapy will be made available to all chronic wound patients worldwide.
AOTI Enters Into Multi-Million USD Strategic Relationship for Chinese Market
OCEANSIDE, Calif., Jan. 18, 2019 /PRNewswire/ -- AOTI Inc. announced today that it has entered into a major strategic relationship with a leading Chinese medical company, Nanning Xinzizhu Trading Co.,Ltd, for distribution of its patented Topical Wound Oxygen (TWO2)...
AOTI to Participate at Jefferies 2018 London Healthcare Conference and Present at the 3rd Annual INV€$TIVAL Showcase in Partnership with Jefferies
OCEANSIDE, Calif., Oct. 18, 2018 /PRNewswire/ -- AOTI Inc. announced today that it will participate at Jefferies 2018 London Healthcare Conference, being held on November 14 and 15, 2018 in London, United Kingdom. Now in its ninth year, the Jefferies conference is the...
TWO2 Randomized Controlled Trial Chosen as One of the Best Abstracts Presented at the Leading Diabetic Foot Global Conference
OCEANSIDE, Calif., Oct. 11, 2018 /PRNewswire/ -- AOTI Inc. announced today that expanded results from its recently concluded Randomized Controlled Trial (RCT) demonstrating the efficacy of its patented multi-modality Topical Wound Oxygen (TWO2) homecare therapy in...
Opening of New Manufacturing Facility to Meet Expanding Demand for Topical Wound Oxygen (TWO2) Therapy Devices
We are delighted to invest in this new facility that will allow us to more effectively ramp up production of our unique multi-modality wound care therapy product line to meet our continually expanding supply needs,” stated Dr. Mike Griffiths, Chief Executive Officer and President of AOTI.
Breakthrough Randomized Controlled Trial Demonstrating TWO2 Efficacy in Healing Diabetic Foot Ulcers unveiled at the American Diabetes Association 78th Scientific Sessions Conference
This breakthrough study unequivocally demonstrates at the highest scientific level the efficacy of Cyclical Pressure Topical Wound Oxygen Therapy in healing Diabetic Foot Ulcers” stated Dr. Robert Frykberg, the Chief Principle Investigator of the study.
Unprecedented Study Results Demonstrating Topical Wound Oxygen Effectiveness Presented at Major Wound Care Conferences
The study was a two-year retrospective review of 71 patients with a total of 115 wounds treated by a Veterans Affairs hospital in Chicago that prescribed cyclical pressurized TWO2 therapy for use at home.
AOTI Inc. Announces New York City Office Grand Opening
AOTI Inc. announced today that its fully owned USA-operating subsidiary, Advanced Oxygen Therapy Inc., has recently opened a New York City Office in Yonkers, New York to support the ever-increasing usage of its unique Topical Wound Oxygen (TWO2) homecare therapy. This new East Coast location has also been approved by the Accreditation Commission for Health Care (ACHC) under the company’s DMEPOS accreditation for Home/Durable Medical Equipment Services.
Topical Wound Oxygen (TWO2) Therapy Receives Strong Evidence Based Treatment Recommendations
OCEANSIDE, Calif., May 10, 2017 /PRNewswire/ -- AOTI Inc. announced today that its revolutionary patented Topical Wound Oxygen (TWO2) homecare therapy has received a Strong GRADE 1B Treatment recommendation in the European Wound Management Association (EWMA) guidance...